coronaviru
diseas
becom
major
global
issu
rise
number
infect
individu
mortal
recent
month
among
therapeut
approach
argument
rais
hydroxychloroquin
efficaci
treatment
aim
overcom
controversi
regard
effect
hydroxychloroquin
treatment
use
systemat
review
metaanalysi
systemat
search
perform
pubm
scopu
embas
cochran
librari
web
scienc
googl
scholar
medrxiv
preprint
databas
use
avail
mesh
term
hydroxychloroquin
two
author
select
assess
qualiti
studi
independ
use
relat
checklist
data
extract
includ
studi
analyz
use
cma
v
heterogen
also
assess
use
isquar
test
seven
studi
includ
four
clinic
trial
three
observ
studi
enter
studi
result
metaanalysi
clinic
trial
show
signific
differ
patient
receiv
standard
treatment
hcq
regimen
patient
receiv
standard
treatment
without
hcq
rr
ci
ctscan
find
improv
ci
nasopharyng
cultur
follow
rtpcr
result
neg
ci
patient
receiv
hydroxychloroquin
metaanalysi
observ
studi
show
ci
patient
discharg
hospit
ci
admit
intens
care
unit
ci
expir
studi
indic
clinic
benefit
regard
hcq
treatment
patient
howev
larg
clinic
trial
taken
account
order
achiev
reliabl
find
novel
coronaviru
emerg
wuhan
china
decemb
name
respiratori
syndrom
coronaviru
declar
pandem
world
health
organ
march
accord
worldomet
metric
novel
viru
respons
approxim
infect
death
worldwid
april
although
month
pass
sinc
onset
new
challeng
diseas
still
specif
prevent
therapeut
approach
regard
therefor
quarantin
approach
person
hygien
social
distanc
basic
protect
measur
coronaviru
diseas
covid
accord
advis
public
moreov
accord
high
volum
ongo
research
regard
pandem
issu
mani
controversi
aris
daili
among
differ
field
scienc
confront
pandem
infodem
eg
coronaviru
surviv
airborn
transmit
vertic
pregnanc
everyon
wear
mask
long
viru
surviv
surfac
possibl
get
second
time
etc
regard
one
hottest
controversi
hydroxychloroquin
hcq
efficaci
patient
sever
studi
talk
hope
effect
hcq
infect
prevent
treatment
other
tri
come
neutral
even
harm
effect
drug
patient
ampl
evid
unavoid
controversi
affect
patient
outcom
significantli
henc
carri
rapid
systemat
review
metaanalysi
order
overcom
controversi
regard
efficaci
hcq
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
follow
studi
design
search
protocol
screen
report
systemat
search
perform
via
databas
pubm
scopu
embas
cochran
librari
web
scienc
googl
scholar
intitl
well
preprint
databas
medrxiv
april
moreov
gray
literatur
refer
elig
paper
consid
avail
data
regard
search
strategi
includ
mesh
term
free
keyword
found
hydroxychloroquin
timeloc
limit
search
two
research
ah
kh
screen
select
paper
independ
discuss
solv
disagr
thirdparti
studi
met
follow
criteria
includ
metaanalysi
studi
clinic
trial
observ
studi
report
effect
hcq
patient
studi
exclud
anim
studi
review
case
report
vitro
studi
duplic
public
insuffici
calcul
desir
paramet
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
two
research
ash
ah
independ
evalu
qualiti
assess
studi
extract
data
select
paper
supervisor
dsh
resolv
disagr
step
data
extract
checklist
includ
name
first
author
public
year
region
studi
number
patient
number
control
mean
age
treatment
choic
treatment
dosag
treatment
durat
advers
effect
radiolog
result
cultur
statu
mortal
jadad
scale
robinsi
tool
newcastleottawa
scale
no
checklist
use
valu
select
random
clinic
trial
nonrandom
clinic
trial
observ
studi
respect
relat
variou
aspect
methodolog
studi
process
riskofbia
plot
creat
robvi
onlin
tool
statist
analysi
perform
use
cma
v
softwar
assess
heterogen
use
isquar
test
accord
studi
heterogen
pool
result
use
randomeffect
model
public
bia
evalu
egger
begg
test
done
databas
search
result
paper
eleven
duplic
paper
exclud
first
step
screen
five
paper
assess
elig
final
five
paper
enter
qualit
synthesi
three
studi
enter
metaanalysi
prisma
flow
diagram
studi
select
process
present
figur
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
six
studi
enter
metaanalysi
three
studi
clinic
trial
three
observ
hcq
arm
clinic
trial
combin
observ
studi
effect
size
metaanalysi
studi
sampl
size
rang
includ
particip
characterist
studi
enter
metaanalysi
present
tabl
accord
qualiti
assess
use
jadad
robin
no
checklist
studi
earn
minimum
elig
score
enter
metaanalysi
summari
risk
bia
present
fig
metaanalysi
risk
ratio
rr
show
signific
differ
case
group
receiv
standard
treatment
hcq
regimen
control
group
receiv
standard
treatment
without
hcq
rr
ci
fig
ctscan
improv
observ
case
ci
control
group
ci
nasopharyng
cultur
result
neg
rtpcr
evalu
hcq
group
ci
control
group
ci
mild
advers
effect
observ
patient
hcq
group
ci
forrest
plot
present
fig
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
fig
observ
natur
studi
metaanalysi
show
ci
patient
discharg
hospit
wherea
ci
patient
admit
intens
care
unit
icu
ci
expir
also
nasopharyng
cultur
result
neg
rtpcr
evalu
patient
ci
ctscan
improv
observ
ci
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
recent
investig
indic
high
concentr
cytokin
plasma
call
cytokin
storm
would
relat
sever
patient
situat
medic
transposit
critic
need
find
effect
antiinflammatori
agent
order
decreas
cytokin
proinflammatori
factor
product
regard
hcq
known
effect
antiinflammatori
agent
long
time
sinc
especi
autoimmun
disord
besid
outcom
new
experiment
studi
conduct
liu
et
al
mention
titl
public
follow
hydroxychloroquin
less
toxic
deriv
chloroquin
effect
inhibit
infect
vitro
also
investig
result
vitro
studi
yao
et
al
addit
pagliano
et
al
letter
editor
clinic
infecti
diseas
cid
journal
recommend
use
hcq
prepostexposur
prophylaxi
infect
health
care
staff
expos
viru
contamin
environ
contrast
maurizio
guastalegnam
alfredo
vallon
claim
useless
even
harm
effect
hcq
letter
editor
journal
actual
believ
pathogen
still
unknown
caution
regard
treatment
decis
prove
vitro
base
studi
order
avoid
dire
paradox
consequ
like
happen
treatment
chikungunya
viru
infect
chloroquin
moreov
molina
et
al
follow
patient
hcq
azithromycin
regimen
conclud
clinic
benefit
reason
antivir
activ
regard
addit
preprint
quasirandom
compar
studi
conduct
detroit
michigan
indic
clinic
benefit
hcq
even
increas
need
urgent
respiratori
support
also
hj
kim
et
al
opinion
public
global
rheumatolog
allianc
point
shortag
hcq
follow
sudden
high
demand
gautret
colleagu
public
march
also
refer
hcq
crucial
treatment
choic
patient
system
lupu
erythematosu
rheumatoid
arthriti
disord
get
troubl
find
hcq
critic
time
author
recommend
scientif
commun
cautiou
rush
decis
ampl
evid
subject
especi
critic
situat
lead
irrepar
consequ
fact
even
efficaci
hcq
confirm
world
face
new
issu
rheumat
disord
patient
shortag
hydroxychloroquin
case
carri
present
systemat
review
order
reach
clear
result
regard
take
nottak
hcq
studi
although
risk
ratio
higher
signific
differ
hcq
arm
receiv
mg
hcq
daili
regimen
standard
treatment
arm
howev
case
hcq
group
present
improv
ctscan
result
neg
swap
cultur
compar
control
group
analysi
result
indic
consider
perform
hcq
regimen
due
small
number
studi
small
sampl
size
earli
reach
reliabl
decis
therefor
urgent
need
aris
comprehens
random
control
trial
order
investig
efficaci
safeti
hcq
consumpt
patient
regard
search
clinic
trial
registri
databas
intern
clinic
trial
registri
platform
ictrp
clinicaltrialsgov
center
watch
chines
clinic
trial
registri
intern
standard
randomis
control
trial
number
isrctn
eu
clinic
trial
regist
opentri
iranian
registri
clinic
trial
result
regist
trial
regard
efficaci
safeti
prophylaxi
potenc
hcq
patient
henc
near
futur
result
trial
help
medic
commun
reach
gener
opinion
regard
util
hcq
prepost
exposur
well
treatment
choic
patient
infect
knowledg
first
systemat
review
carri
metaanalysi
investig
role
hcq
patient
howev
releas
outcom
way
clinic
trial
updat
systemat
review
metaanalysi
subject
could
conclud
reliabl
result
full
confid
studi
indic
clinic
effect
regard
role
hcq
treatment
patient
howev
larg
clinic
trial
taken
account
order
achiev
reliabl
find
